Glucagon-like peptide 1 (GLP-1): a potent gut hormone with a possible therapeutic perspective
The DOI matches its Crossref record; 145 of the 146 references it cites were found in a registry or an index.
Abstract
Glucagon-like peptide 1 (GLP-1) is a physiological incretin hormone from the lower gastrointestinal tract, partially explaining the augmented insulin response after oral compared to intravenous glucose administration in normal humans. In addition, GLP-1 also lowers glucagon concentrations, slows gastric emptying, stimulates (pro)insulin biosynthesis, and reduces food intake upon intracerebroventricular administration in animals. Therefore, GLP-1 offers some interesting perspective for the treatment of type 2, and perhaps also for type 1 diabetic patients. The other incretin hormone, gastric inhibitory polypeptide (GIP), has lost almost all its activity in type-2 diabetic patients. In contrast, GLP-1 glucose-dependently stimulates insulin secretion in type-2 diabetic patients and exogenous administration of GLP-1 ([7-37] or [7-36 amide]) in doses elevating plasma concentrations to approximately three to four times physiological postprandial levels fully normalizes fasting hyperglycaemia and reduces postprandial glycaemic increments. Due to rapid proteolytic cleavage, which results in an inactive or even antagonistic fragment. GLP-1 [9-36 amide], and to rapid elimination, the half-life of GLP-1 is too short to maintain therapeutic plasma levels for sufficient periods by subcutaneous injections of the natural peptide hormone. Current research aims to characterize GLP-1 analogues with more suitable pharmacokinetic properties than the original peptide. Given the large amount of GLP-1 present in L cells, it also appears worthwhile to search for more agents that could 'mobilize' this endogenous pool of GLP-1.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“GLP-1, a 30- or 31-amino-acid-long peptide hormone, is a gastrointestinal peptide secreted by the intestinal tract that potentiates insulin release and reduces glucagon’s concentration in physiological conditions (15, 16).”
From GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach (2023) · cites this paper as [16]
In the citing paper
“Besides lowering blood glucose and reducing weight (incredibly visceral fat), GLP-1R agonists can also lower blood pressure, improve blood lipid disorder, and reduce fatty liver (16, 140).”
From GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach (2023) · cites this paper as [16]
In the citing paper
“Besides lowering blood glucose and reducing weight (incredibly visceral fat), GLP-1R agonists can also lower blood pressure, improve blood lipid disorder, and reduce fatty liver (16, 140).”
From GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach (2023) · cites this paper as [16]
In the citing paper
“Besides lowering blood glucose and reducing weight (incredibly visceral fat), GLP-1R agonists can also lower blood pressure, improve blood lipid disorder, and reduce fatty liver (16, 140).”
From GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach (2023) · cites this paper as [16]
In the citing paper
“Besides lowering blood glucose and reducing weight (incredibly visceral fat), GLP-1R agonists can also lower blood pressure, improve blood lipid disorder, and reduce fatty liver (16, 140).”
From GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach (2023) · cites this paper as [16]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
A role for glucagon-like peptide-1 in the central regulation of feeding
Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., et al. (1996) · Nature · doi:10.1038/379069a0 · Cited by 1,950
Glucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928
Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
Self-citationGlucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402
MENTLEIN, R., GALLWITZ, B., & SCHMIDT, W. E. (1993) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1993.tb17986.x · Cited by 1,161
Kieffer, T. J., McIntosh, C. H., & Pederson, R. A. (1995) · Endocrinology · doi:10.1210/endo.136.8.7628397 · Cited by 1,124
Tissue and Plasma Concentrations of Amidated and Glycine-Extended Glucagon-Like Peptide I in Humans
Ørskov, C., Rabenhøj, L., Wettergren, A., Kofod, H., & Holst, J. J. (1994) · Diabetes · doi:10.2337/diab.43.4.535 · Cited by 919
Plasma Insulin Responses to Oral and Intravenous Glucose: Studies in Normal and Diabetic Subjects*
Perley, M. J., & Kipnis, D. M. (1967) · Journal of Clinical Investigation · doi:10.1172/jci105685 · Cited by 917
Thorens, B. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.18.8641 · Cited by 906
Mojsov, S., Weir, G. C., & Habener, J. F. (1987) · Journal of Clinical Investigation · doi:10.1172/jci112855 · Cited by 882
Cited by
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
Self-citationGastrointestinal hormones and food intake
Strader, A. D., & Woods, S. C. (2005) · Gastroenterology · doi:10.1053/j.gastro.2004.10.043 · Cited by 447
Talsania, T., Anini, Y., Siu, S., Drucker, D. J., & Brubaker, P. L. (2005) · Endocrinology · doi:10.1210/en.2005-0473 · Cited by 306
“agonist (24), the truncated form of PYY remains biologically”
BackgroundGLP−1 receptor agonists for the treatment of obesity: Role as a promising approach
Wang, J.-Y., Wang, Q.-W., Yang, X.-Y., Yang, W., Li, D.-R., Jin, J.-Y., Zhang, H.-C., & Zhang, X.-F. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1085799 · Cited by 248
“Frontiers in Endocrinology 02 GLP-1, a 30- or 31-amino-acid-long peptide hormone, is a gastrointestinal peptide secreted by the intestinal tract that potentiates insulin release and reduces glucagon’s concentration in physiological conditions (15, 16).”
BackgroundWhat do we know about the secretion and degradation of incretin hormones?
Deacon, C. F. (2005) · Regulatory Peptides · doi:10.1016/j.regpep.2004.06.007 · Cited by 241
Food protein-derived bioactive peptides in management of type 2 diabetes
Patil, P., Mandal, S., Tomar, S. K., & Anand, S. (2015) · European Journal of Nutrition · doi:10.1007/s00394-015-0974-2 · Cited by 231
“Taking into consideration that sugar absorption plays a significant role in GLP-1 secretion [94, 95] and that lower gut is plentiful in GLP-1 producing cells [96, 97], delayed carbohydrate absorption is considered a satisfactory contributing factor for stimulating GLP-1 secretion by alphaglucosidase inhibition.”
BackgroundLynn, F. C., Pamir, N., Ng, E. H. C., McIntosh, C. H. S., Kieffer, T. J., & Pederson, R. A. (2001) · Diabetes · doi:10.2337/diabetes.50.5.1004 · Cited by 208
“Glucose-dependent insulinotropic polypeptide (GIP) (gastric inhibitory polypeptide), the proglucagon gene–derived glucagon-like peptide (GLP)-1(7-37), and the COOH-terminal truncated form GLP-1(7-36) amide are the major incretins that act via this endocrine system to potentiate glucose-induced insulin secretion (1).”
BackgroundRiyaphan, J., Pham, D.-C., Leong, M. K., & Weng, C.-F. (2021) · Biomolecules · doi:10.3390/biom11121877 · Cited by 162
“GLP-1, which is a physiological incretin hormone from the lower gastrointestinal (GI) tract [212], is produced from the proglucagon gene in the L cell of the small intestine and secreted in response to nutrients.”
BackgroundHolz, G., & Chepurny, O. (2003) · Current Medicinal Chemistry · doi:10.2174/0929867033456648 · Cited by 131
Physiology of Incretins in Health and Disease
Deacon, C. F., & Ahrén, B. (2011) · The Review of Diabetic Studies · doi:10.1900/rds.2011.8.293 · Cited by 126
“Calculation of the amount of GLP-1 present in the upper intestine indicates that this is more than sufficient to account for the GLP-1 response to oral glucose [59].”
BackgroundThazhath, S. S., Wu, T., Bound, M. J., Checklin, H. L., Standfield, S., Jones, K. L., Horowitz, M., & Rayner, C. K. (2015) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.115.117440 · Cited by 129
Protein based therapeutic delivery agents: Contemporary developments and challenges
Yin, L., Yuvienco, C., & Montclare, J. K. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.04.036 · Cited by 114
“GLP is a 30 amino acid peptide release by gastrointestinal cells, stimulating the release of insulin from pancreatic βcells [249].”
Valverde, I., Puente, J., Martín‐Duce, A., Molina, L., Lozano, O., Sancho, V., Malaisse, W. J., & Villanueva‐Peñacarrillo, M. L. (2005) · Obesity Surgery · doi:10.1381/0960892053576613 · Cited by 127
Amiram, M., Luginbuhl, K. M., Li, X., Feinglos, M. N., & Chilkoti, A. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.07.021 · Cited by 105
Hui, H., Zhao, X., & Perfetti, R. (2005) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.553 · Cited by 97
“(DPP-IV), leading to its very short half-life [21].”
BackgroundAmiram, M., Luginbuhl, K., Li, X.-H., Feinglos, M., & Chilkoti, A. (2013) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.1214518110 · Cited by 90
“11 of GLP-1(7-36) amide and comparison of the substrate specificity”
BackgroundIncretins and the development of type 2 diabetes
Meier, J. J., & Nauck, M. A. (2006) · Current Diabetes Reports · doi:10.1007/s11892-006-0034-7 · Cited by 105
“Although the insulinotropic effect of GLP-1 may vary somewhat in patients with type 2 diabetes, depending on the stage of the disease and overall β-cell function (and presumably mass) [42,45, 47 ], the other effects of GLP-1 seem to be fully preserved.”
BackgroundSelf-citationSubramaniyan, V., & Hanim, Y. U. (2025) · International Journal of Obesity · doi:10.1038/s41366-025-01729-1 · Cited by 112
“It was identi fi ed in 1983 as a product of proglucagon conversion by L cells in the lining of the intestines and is also produced by pancreatic α -cells, as well as being present in islet β -cells and the intestine [82].”
Wu, J.-D., Xu, X.-H., Zhu, J., Ding, B., Du, T.-X., Gao, G., Mao, X.-M., Ye, L., Lee, K.-O., & Ma, J.-H. (2011) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2010.0048 · Cited by 89
“GLP1 also lowers glucagon concentrations, slows gastric emptying, stimulates pro-insulin biosynthesis and secretion, reduces food intake, and may enhance insulin sensitivity.(15) However, the half-life of GLP-1 (<2 min) is too short to maintain a therapeutic level for treatment of diabetes as circulating GLP1 undergoe…”
Bertin, É., Arner, P., Bolinder, J., & Toft, E. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.3.7330 · Cited by 110
What Is an L-Cell and How Do We Study the Secretory Mechanisms of the L-Cell?
Kuhre, R. E., Deacon, C. F., Holst, J. J., & Petersen, N. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.694284 · Cited by 93
“org 4 found to be 3-5 times higher in jejunum and ileum compared to colon and rectum (60).”
BackgroundThe incretins: a link between nutrients and well-being
Burcelin, R. (2005) · British Journal of Nutrition · doi:10.1079/bjn20041340 · Cited by 70
“The corresponding gene is expressed in the intestine (L cells), the pancreatic islets ( a -cells) and in the brain (Drucker, 1990; Creutzfeldt, 1992; Thorens & Waeber, 1993; Holst, 1997; Blazquez et al. 1998; Nauck, 1998; Goldstone et al. 2000).”
Gevrey, J., Body–Malapel, M., Philippé, J., Mithieux, G., Chayvialle, J. A., Abello, J., & Cordier–Bussat, M. (2004) · Diabetologia · doi:10.1007/s00125-004-1380-0 · Cited by 59
“It is well established that nutrients are physiological stimulants of GLPs secretion in vivo [1].”
BackgroundInfluentialThe regulation of function, growth and survival of GLP-1-producing L-cells
Kuhre, R. E., Holst, J. J., & Krizhanovskii, C. (2015) · Clinical Science · doi:10.1042/cs20150154 · Cited by 54
A role for the gut-to-brain GLP-1-dependent axis in the control of metabolism
Burcelin, R., Sérino, M., & Cabou, C. (2009) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2009.09.003 · Cited by 52
Forgotten and novel aspects in pancreas development
Pieler, T., & Chen, Y. (2006) · Biology of the Cell · doi:10.1042/bc20050069 · Cited by 47
“prohormone leads to production of two different glucagon related peptides, GLP-1 and GLP-2, the former one having an antagonistic relationship to glucagon in stimulating insulin secretion upon food uptake (Irwin et al., 1997; Nauck, 1998).”
BackgroundKuhre, R. E., Christiansen, C. B., Saltiel, M. Y., Wewer Albrechtsen, N. J., & Holst, J. J. (2017) · Physiological Reports · doi:10.14814/phy2.13507 · Cited by 40
“However, conventional analysis does not take into account the differences in surface area and length of the different regions of the intestine; if this is done, one may find in humans that although sparse in density, the total L-cell numbers are higher in the upper jejunum and ileum than in the large intestine (Nauck…”
BackgroundDysfunctional insulin secretion in type 2 diabetes: role of metabolic abnormalities
Grill, V., & Björklund, A. (2000) · Cellular and Molecular Life Sciences · doi:10.1007/pl00000705 · Cited by 41
Preclinical developments in type 2 diabetes
Lenhard, J. M., & Gottschalk, W. K. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00092-3 · Cited by 44
Targeting amyloid-beta by glucagon-like peptide -1 (GLP-1) in Alzheimer's disease and diabetes
Bak, A. M., Egefjord, L., Gejl, M., Steffensen, C., Stecher, C. W., Smidt, K., Brock, B., & Rungby, J. (2011) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.600691 · Cited by 36
“It inhibits glucagon secretion, reduces food intake by promotion of satiety, slows gastric emptying, induces proliferation and differentiation of betacells in the pancreas and protect beta-cells from apoptosis, (Figure 1) [38,39].”
BackgroundChapter 19. DPP-IV inhibition and therapeutic potential
Villhauer, E. B., Coppola, G. M., & Hughes, T. E. (2001) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(01)36059-1 · Cited by 36
Recent Developments and Emerging Therapies for Type 2 Diabetes Mellitus
Evans, A. J., & Krentz, A. J. (1999) · Drugs in R&D · doi:10.2165/00126839-199902020-00001 · Cited by 36
Nishimura, K., Hiramatsu, K., Monir, M. M., Takemoto, C., & Watanabe, T. (2013) · Journal of Veterinary Medical Science · doi:10.1292/jvms.13-0106 · Cited by 34
“This mealinduced gut hormone [2, 7] has many important physiological actions, such as the accentuation of glucose-dependent insulin release, the inhibition of glucagon secretion and the increase of pancreatic B cell growth [5, 8, 15].”
BackgroundYin, D., Lü, Y., Zhang, H., Zhang, G., Zou, H., Sun, D., & Zhong, Y. (2008) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.56.156 · Cited by 31
O'Harte, F. P. M., Mooney, M., Kelly, C., McKillop, A. M., & Flatt, P. R. (2001) · Regulatory Peptides · doi:10.1016/s0167-0115(00)00125-7 · Cited by 27
Åhrén, B., Holst, J. J., & Yu, S. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00261-2 · Cited by 27
Hiramatsu, K., Yamasaki, A., & Shioji, T. (2005) · The Journal of Poultry Science · doi:10.2141/jpsa.42.223 · Cited by 27
Is Glucagon-like peptide-1, an agent treating diabetes, a new hope for Alzheimer’s disease?
Li, L. (2007) · Neuroscience Bulletin · doi:10.1007/s12264-007-0009-y · Cited by 28
“GLP-1 is rapidly degraded in vivo by dipeptidyl peptidase-IV (DPP-IV), leading to its very short half-life (1–2 min)[16,17].”
BackgroundLocal, exendin-(9—39)-insensitive, site of action of GLP-1 in canine ileum
Daniel, E. E., Anvari, M., Fox-Threlkeld, J. E. T., & McDonald, T. J. (2002) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00110.2002 · Cited by 22
“GLP-1 may mediate paracrine action on afferent nerves in the canine ileal mucosa using an unusual receptor. gastric emptying; intestinal motility; capsaicin; afferent nerves; paracrine action GLUCAGON-LIKE PEPTIDE (GLP)-1 is produced in L-type endocrine cells of the ileal and colonic mucosa, where it is usually coloca…”
BackgroundInfluentialThe metabolic syndrome influences the response to incretin-based therapies
Fadini, G. P., de Kreutzenberg, S. V., Gjini, R., & Avogaro, A. (2011) · Acta Diabetologica · doi:10.1007/s00592-011-0296-7 · Cited by 20
“Endogenous incretins (glucagon-like peptide-1 [GLP-1] and glucose-dependent insulinotropic peptide [GIP]) regulate insulin secretion and exert a variety of other effects through receptor binding in several organs and tissues [1].”
Monir, M. M., Hiramatsu, K., Yamasaki, A., Nishimura, K., & Watanabe, T. (2013) · Anatomia Histologia Embryologia · doi:10.1111/ahe.12062 · Cited by 22
“Moreover, GLP-1 has other important biological functions; for example, reduction in food intake (Furuse et al., 1997; Balkan, 2000) and deceleration in gastric emptying (Nauck, 1998; Schirra et al., 2006) and intestinal motility (Tolessa et al., 1998a,b).”
BackgroundInfluentialHiramatsu, K., Yamasaki, A., & Karasawa, Y. (2003) · The Journal of Poultry Science · doi:10.2141/jpsa.40.39 · Cited by 21
Monir, M. M., Hiramatsu, K., Matsumoto, S., Nishimura, K., Takemoto, C., Shioji, T., Watanabe, T., Kita, K., Yonekura, S., & Roh, S. G. (2014) · Animal Science Journal · doi:10.1111/asj.12177 · Cited by 17
“Chickens were treated in accordance with the “Guideline for Regulation of Animal Experimentation (1997)” of the Faculty of Agriculture, Shinshu University.”
MethodRosetta Machine Learning Models Accurately Classify Positional Effects of Thioamides on Proteolysis
Giannakoulias, S. G., Shringari, S. R., Liu, C., Phan, H. A. T., Barrett, T. M., Ferrie, J. J., & Petersson, E. J. (2020) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.0c05981 · Cited by 19
“3 Due to their diverse biochemical properties and applications, peptides have become a standard therapeutic strategy both academically and industrially resulting in tens of new peptide-based pharmaceuticals entering clinical trials annually.”
BackgroundThe dipeptidyl peptidase IV inhibitor NVP-DPP728 reduces plasma glucagon concentration in cats
Furrer, D., Kaufmann, K., Tschuor, F., Reusch, C. E., & Lutz, T. A. (2009) · The Veterinary Journal · doi:10.1016/j.tvjl.2008.11.017 · Cited by 17
Design, synthesis and crystallization of a novel glucagon analog as a therapeutic agent
Li, P., Rogers, T., Smiley, D., DiMarchi, R. D., & Zhang, F. P. Y. (2007) · Acta Crystallographica Section F Structural Biology and Crystallization Communications · doi:10.1107/s1744309107028655 · Cited by 15
“GLP-1 acts as an incretin hormone that stimulates insulin secretion in a glucose-dependent manner (Landsberg, 2006; Nauck et al., 1997; Nauck, 1998).”
BackgroundDietary Synergies in Appetite Control: Distal Gastrointestinal Tract
Woods, S. C. (2006) · Obesity · doi:10.1038/oby.2006.301 · Cited by 15
“agent in the treatment of obesity and type 2 diabetes (71,72).”
BackgroundAhmad, N., Alruwayyes, A., AlArjani, A., Tawhari, A. M., Aldosri, A., Alahmari, A., & Balaha, M. F. H. (2026) · Medicine · doi:10.1097/md.0000000000047994 · Cited by 18
“[13,14] Given the greater weight reduction efficacy and safety of GLP-1 agonists, the Food and Drug Administration has formally authorized several of these medications for chronic weight management of obese or overweight individuals.”
Cho, T. P., Long, Y. F., Gang, L. Z., Wang, Y., Jun, L. H., Yuan, S. G., Hong, F. J., Wang, L., Liang, G. D., Lei, Z., et al. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.04.120 · Cited by 13
Glucagon-like peptide-1 improves insulin and proinsulin binding on RINm5F cells and human monocytes
Ebinger, M., Jehle, D. R., Fussgaenger, R. D., Fehmann, H. C., & Jehle, P. M. (2000) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2000.279.1.e88 · Cited by 13
“In contrast to other drugs for the treatment of type 2 diabetes, GLP-1 possesses a “glucagonostatic” effect that is of high therapeutic relevance (11, 34).”
BackgroundSaxagliptin improves glucose tolerance but not survival in a murine model of dilated cardiomyopathy
Vyas, A. K., Aerni-Flessner, L. B., Payne, M., Kovács, A. D., Jay, P. Y., & Hruz, P. W. (2012) · Cardiovascular Endocrinology · doi:10.1097/xce.0b013e32835bfb24 · Cited by 12
Basal Glucagonlike Peptide 1 Levels and Metabolic Syndrome in Obese Patients
de Luis, D. A., Aller, R., Conde, R., Primo, D., Izaola, O., Castro, M. J., & Sagrado, M. G. (2012) · Journal of Investigative Medicine · doi:10.2310/jim.0b013e3182544f9e · Cited by 12
Cao, L., Zhou, S., Li, J., Chen, K., Xue, X., & Wei, Y. (2023) · Acupuncture in Medicine · doi:10.1177/09645284231207871 · Cited by 11
“37 39–41 Recently, GLP-1 has become widely used in the treatment of DM.”
BackgroundBlaslov, K., Bulum, T., Zibar, K., & Duvnjak, L. S. (2014) · Journal of Diabetes · doi:10.1111/1753-0407.12194 · Cited by 12
“The GLP-1 receptor has a wide tissue distribution and is expressed in brain, cardiac, pancreatic, and peripheral tissue cells.(2) Activation of the GLP-1 receptor leads to appetite suppression, inhibition of gastric motility, enhancement of insulin secretion, and glucagon suppression, all of which together tend to res…”
BackgroundS 23521 Decreases Food Intake and Body Weight Gain in Diet‐Induced Obese Rats
Claret, M., Corominola, H., Canals, I., Nadal, B., Chavanieu, A., Pfeiffer, B., Renard, P., Gorostiaga, C., Delagrange, P., Grassy, G., et al. (2004) · Obesity Research · doi:10.1038/oby.2004.199 · Cited by 11
Amino Acid Supplementation to Diet Influences the Activity of the L Cells in Chicken Small Intestine
Nishimura, K., Hiramatsu, K., Watanabe, T., Makino, R., Sasaki, N., & Kita, K. (2015) · The Journal of Poultry Science · doi:10.2141/jpsa.0150031 · Cited by 11
“GLP-1 is identified as an “incretin hormone” with potent insulin-releasing activity, and it also decelerates gastric emptying (Nauck, 1998; Schirra et al., 2006).”
BackgroundCho, T. P., Gang, L. Z., Long, Y. F., Yang, W., Qian, W., Lei, Z., Jing, L., Ying, F., Ke, Y. P., Leng, Y., et al. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.04.138 · Cited by 10
Efficient synthesis of Aib8‐Arg34‐GLP‐1 (7–37) by liquid‐phase fragment condensation
Zhang, J., Dong, Y., He, Y., Han, J., Hu, H., & Feng, J. (2022) · Journal of Peptide Science · doi:10.1002/psc.3407 · Cited by 9
“However, because of the rapid degradation by dipeptidyl peptidase IV (DPP IV), the half-life of GLP-1 is very short (approximately 5 min) [4].”
BackgroundVoglibose, an Alpha-glucosidase Inhibitor, to Increase Active Glucagon-like Peptide-1 Levels
Moritoh, Y., Takeuchi, K., & Hazama, M. (2009) · Molecular and Cellular Pharmacology · Cited by 12
Semaglutide-Induced Acute Pancreatitis Leading to Death After Four Years of Use
DAGHER, C., Jailani, M., Akiki, M., Siddique, T., Saleh, Z., & Nadler, E. (2024) · Cureus · doi:10.7759/cureus.69704 · Cited by 13
Alam, I., Stephens, J. W., Fielding, A., Lewis, K. E., Lewis, M. J., & BAXTER, J. N. (2011) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2011.10.018 · Cited by 8
Role for DPP4 inhibitor therapy in cystic fibrosis related diabetes: A single centre experience
Santhakumar, A., Lewis, F., Pickles, J., Winterbottom, H., Punt, S., Beynon, J., Tofeec, K., Barry, P. J., & Brennan, A. L. (2024) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2024.06.007 · Cited by 7
The critical role of GLP-1 signaling pathways in the pathology of Parkinson's disease and diabetes
Chen, J., Dong, X., Lin, Y., & Lv, C. (2025) · Pathology - Research and Practice · doi:10.1016/j.prp.2025.155985 · Cited by 7
Wu, S., Zhang, C.-C., Chen, J., Zhang, X., Guan, M., & Geng, C. (2022) · Fitoterapia · doi:10.1016/j.fitote.2022.105336 · Cited by 7
Basal GLP-1 Levels in Morbidly Obese Patients following Biliopancreatic Diversion Surgery
de Luis, D. A., Pacheco, D., Conde, R., Primo, D., Aller, R., & Izaola, O. (2012) · Annals of Nutrition and Metabolism · doi:10.1159/000339378 · Cited by 6
Upper gastrointestinal responses to intraduodenal nutrient in type 1 diabetes mellitus
Rayner, C. K., Schwartz, M. P., van Dam, P. S., Renooij, W., Smet, M. D., Horowitz, M., Wishart, J. M., Smout, A. J. P. M., & Samsom, M. (2004) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-200402000-00010 · Cited by 9
Watanabe, T., Nishimura, K., Monir, M. M., Takemoto, C., & Hiramatsu, K. (2013) · Journal of Veterinary Medical Science · doi:10.1292/jvms.13-0339 · Cited by 7
“This meal-induced gut hormone has many important physiological actions, especially the potentiation of glucose-induced insulin secretion, thereby lowering the plasma glucose levels in mammals [3, 5, 11, 12].”
Nauck, M. A., Schmidt, W. E., & Meier, J. J. (2007) · Springer eBooks · doi:10.1007/978-0-387-69737-6_12 · Cited by 5
“Liraglutide (NN2211; Arg34, Lys26-[N-∈ (γGlu[N-α-hexadecanoyl])]-GLP-1[7–37]) is a GLP-1 derivative developed by Novo Nordisk, which is currently undergoing phase 3 clinical trials.”
BackgroundInfluentialSelf-citationAssessment of anti-diabetic effect of Vietnamese herbal drugs
Nguyen, K. (2005) · Figshare · Cited by 5
Hashiguchi, S., Yada, T., & Arima, T. (2001) · PubMed · Cited by 5
Björklund, A., & Grill, V. (2000) · Journal of Endocrinology · doi:10.1677/joe.0.1660537 · Cited by 4
“…note that the adenylate cyclase stimulators glucagon and GLP-1 can induce insulin secretion in type 2 diabetic patients (Gutniak et al. 1992, Holst 1996, Nauck 1998) and that such stimulation is observed under conditions of over-stimulation and -cell insensitivity to glucose (Castillo et al. 1996).”
BackgroundMolecular engineering approaches to half-life extension of therapeutic biomolecules
WANG, Y., Chang, J., & Liu, J. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1778569 · Cited by 4
“For instance, native glucagon-like peptide-1 (GLP-1) exhibits an exceptionally short half-life of approximately 2 min (Nauck, 1998), while interferon-β 1b lasts merely 4–15 h after intravenous injection (Harari et al., 2015).”
Editorial: Proglucagon-Derived Peptides
Flatt, P. R., Knop, F. K., & Tarasov, A. I. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.776871 · Cited by 3
Rosseel, R., Vandermeulen, G., Dehau, T., & Verbeke, K. (2026) · American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2026.101470 · Cited by 2
Salahuddin, M., Hiramatsu, K., & Kita, K. (2021) · Domestic Animal Endocrinology · doi:10.1016/j.domaniend.2021.106693 · Cited by 2
Ding, B., Lenzi, C., & Pirone, A. (2013) · The Journal of Poultry Science · doi:10.2141/jpsa.0120167 · Cited by 2
“It stimulates glucose-dependent insulin secretion and insulin biosynthesis, inhibits glucagon secretion and gastric emptying, and inhibits food intake in mammals (Schirra et al., 1996; Furuse et al., 1997; Nauck 1998).”
BackgroundDietary carbohydrate modifies the density of L cells in the chicken ileum
Salahuddin, M., Hiramatsu, K., NISHIMOTO, I., & Kita, K. (2021) · Journal of Veterinary Medical Science · doi:10.1292/jvms.21-0572 · Cited by 2
“Some of these functions include enhancing glucose-dependent insulin release, inhibiting glucagon secretion, increasing pancreatic β cell growth [10, 27], decreasing food intake [1], decelerating gastric emptying [27], inhibiting intestinal motility [36], and stimulating intestinal growth [21].”
Background[American Gastroenterological Association. Gastrointestinal hormones and food intake].
Strader, A. D., & Woods, S. C. (2005) · PubMed · Cited by 3
Carbohydrate and Fat-Based Appetite Control Mechanisms
Langhans, W. (2001) · KARGER eBooks · doi:10.1159/000061842 · Cited by 2
“These mechanisms, collectively termed the ‘ileal break’, have traditionally been invoked mainly during the delivery of abnormal amounts of undigested nutrients into the distal intestine [16].”
InfluentialLow Molecular-Mass Hormones: Peptidic and Steroidal Hormones
Gelves, L. G. V., Trindade, A. C. L. B., & Lima, L. M. (2024) · Topics in medicinal chemistry · doi:10.1007/7355_2024_176 · Cited by 2
amin, M. A., Salahuddin, M., Imai, Y., & Hiramatsu, K. (2023) · The Journal of Poultry Science · doi:10.2141/jpsa.2023029 · Cited by 2
“This gut hormone is induced through the ingestion of a meal and has numerous biological functions, including reducing food intake[4], initiating glucose-dependent insulin release, gastric emptying declaration[6,7] and inhibiting intestinal motility[8,9].”
BackgroundCancelas, J., Villanueva‐Peñacarrillo, M. L., Valverde, I., & Malaisse, W. J. (2001) · Endocrine · doi:10.1385/endo:16:2:113 · Cited by 2
Hashiguchi, S., Yada, T., & Arima, T. (2001) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29658-0 · Cited by 5
Studies on factors modulating glucose homeostasis in healthy and diabetic rats
Yassin, K. (2011) · Figshare
Hagde, K., & Nielsen, M. L. (2011)
Köthe, L. (2011) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-1062
Tilley, J. (2001) · Kirk-Othmer Encyclopedia of Chemical Technology · doi:10.1002/0471238961.0114200920091212.a01.pub2
Estabile, P. C. (2023) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2023.tde-27092023-160305
Regulation of Metabolism and Exercise Functions Associated with Skeletal Muscle and Gut Crosstalk
Aoi, W. (2023) · Nippon Eiyo Shokuryo Gakkaishi · doi:10.4327/jsnfs.76.305
Conrad, M. (2024) · The Conversation · doi:10.64628/aai.xeqxva47a
Rhouma-Martin, G. B. (2013) · theses.fr (ABES) · doi:10.70675/cef3e328z8878z4207zab5ez6c04c60d91d7 · Cited by 3
Tuttle, Z., & Niewiadomski, O. (2026) · Journal of Parenteral and Enteral Nutrition · doi:10.1002/jpen.70131
Metadata
- Authors
- Nauck, M. A.
- Affiliations
- Universitätsklinikum Knappschaftskrankenhaus Bochum (DE)
- Corresponding author
- Nauck, M. A.
- ORCID
- Nauck, M. A.
- Venue
- Acta Diabetologica
- Published
- 1998-10-23
- Volume
- 35
- Issue
- 3
- Pages
- 117-129
- ISSN
- 0940-5429 (ISSN-L)
- 1432-5233
- OpenAlex
- W2079136334
- Cited by
- 94
- References
- 146
- Citations by year
- 2026: 4 · 2025: 2 · 2024: 5 · 2023: 5 · 2022: 2 · 2021: 5 · 2020: 1 · 2019: 1 · 2017: 2 · 2015: 4 · 2014: 2 · 2013: 7 · 2012: 3
- FWCI
- 3.14
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Acta Diabetologica (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- glucagon-like peptide-1, incretins, type 2 diabetes, type 1 diabetes, insulin secretion, glucose-dependent insulinotropic polypeptide, GLP-1 analogues, pharmacokinetics, gastric emptying, dietary intake, gastrointestinal hormones, L cells, fasting hyperglycemia, postprandial blood glucose
- MeSH terms
- Animals, Cerebral Ventricles, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Feeding Behavior, Gastric Emptying, Glucagon, Glucose, Humans, Insulin, Models, Biological, Peptide Fragments, Proinsulin, Protein Precursors, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.